Clinical Trials | May 21, 2024
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
EBITDA before special items falls 1.3 percent to € 4.41 billion
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Investing in Malaysia's largest clinic operator to expand the healthcare business
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subscribe To Our Newsletter & Stay Updated
